ArticleCureus2026
Limited Access to Blinatumomab in Morocco: Challenges and Implications.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in hematology, particularly immunotherapy, have significantly improved outcomes in acute lymphoblastic leukemia (ALL). Blinatumomab, a CD19-directed bispecific T-cell engager, has demonstrated substantial efficacy in relapsed or refractory B-cell ALL, achieving high rates of minimal residual disease negativity and improving overall survival. However, there are still disparities in how these therapeutic advancements are incorporated into standard clinical practice across the globe. Financial obstacles, restricted drug availability, and regulatory delays often impede access to novel agents like blinatumomab in Morocco and other middle-income countries. As a result, despite the mounting evidence in favor of immunotherapy-driven approaches, many patients still receive traditional chemotherapy. This editorial highlights the gap between international standards of care and real-world practice in Morocco and underscores the urgent need to improve equitable access to life-saving hematologic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.